HALIFAX, NS, Aug. 27, 2026 /PRNewswire/ -- The combined expertise of Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, and its subsidiaries Affinity Biologicals and George King Bio-Medical, is capturing the attention of hemostasis clinicians and researchers around the globe.
Since last fall when Precision BioLogic announced the expanded utility of its CRYOcheck™ Chromogenic Factor VIII assay in anticipation of emerging hemophilia treatments such as Mim8, a next generation bispecific antibody for the treatment of hemophilia A, the inquiries haven't stopped. In fact, they're increasing given Nova Nordisk's submission of Mim8 to the U.S. FDA.
"We exhibited at ISTH 2026 in Paris this summer and fielded a lot of questions about our bovine Chromogenic Factor VIII and its ability to accurately measure factor VIII in the presence of not only extended half-life FVIII replacement products but also emerging FVIIIa mimetic bispecific antibodies," says Paul Empey, President and CEO of Precision BioLogic. "There's a growing awareness of the need for chromogenic assays and we're here to ensure coagulation labs are ready and able to deliver accurate results," he adds.The company's research capabilities were also on display at ISTH with the presentation of two scientific posters, which are now available from the Precision BioLogic website:
